PE20120204A1 - Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas - Google Patents
Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicasInfo
- Publication number
- PE20120204A1 PE20120204A1 PE2011001039A PE2011001039A PE20120204A1 PE 20120204 A1 PE20120204 A1 PE 20120204A1 PE 2011001039 A PE2011001039 A PE 2011001039A PE 2011001039 A PE2011001039 A PE 2011001039A PE 20120204 A1 PE20120204 A1 PE 20120204A1
- Authority
- PE
- Peru
- Prior art keywords
- formulation
- macromolecle
- aggregation
- reduce
- physiological conditions
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000002776 aggregation Effects 0.000 title 1
- 238000004220 aggregation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000004962 physiological condition Effects 0.000 title 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 235000017281 sodium acetate Nutrition 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 229940074409 trehalose dihydrate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
Abstract
REFERIDA A UNA FORMULACION QUE COMPRENDE: A) UNA MACROMOLECULA TAL COMO ANTICUERPO ANTI-CD20, DONDE EL ANTICUERPO COMPRENDE LA SECUENCIA DE AMINOACIDOS SELECCIONADA DEL GRUPO FORMADO POR SEC ID NO:1-15 Y ESTA PRESENTE EN LA FORMULACION EN UN RANGO DE CONCENTRACION DE 30-150 mg/mL; B) DE 5-20% DE POLIVINILPIRROLIDONA (PVP) QUE TIENE UN RANGO DE PESO MOLECULAR DE 2000-54000 DALTONS; C) 30mM DE ACETATO DE SODIO, 5% DE DIHIDRATO DE TREHALOSA Y 0,03% DE POLISORBATO 20, A pH 5.3. DICHA FORMULACION ES UTIL PARA REDUCIR AL MINIMO LA INFLAMACION EN EL SITIO DE INYECCION DURANTE LA ADMINISTRACION DEL ANTICUERPO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11543908P | 2008-11-17 | 2008-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120204A1 true PE20120204A1 (es) | 2012-03-03 |
Family
ID=42170394
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001039A PE20120204A1 (es) | 2008-11-17 | 2009-11-16 | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
| PE2014001174A PE20142332A1 (es) | 2008-11-17 | 2009-11-16 | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014001174A PE20142332A1 (es) | 2008-11-17 | 2009-11-16 | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20110300135A1 (es) |
| EP (1) | EP2358394A4 (es) |
| JP (2) | JP2012509270A (es) |
| KR (2) | KR20110097772A (es) |
| CN (2) | CN103705930A (es) |
| AR (1) | AR074196A1 (es) |
| AU (1) | AU2009313756B2 (es) |
| BR (1) | BRPI0916042A2 (es) |
| CA (1) | CA2742990A1 (es) |
| CL (1) | CL2011001131A1 (es) |
| IL (1) | IL212532A0 (es) |
| MX (1) | MX2011005056A (es) |
| PE (2) | PE20120204A1 (es) |
| RU (1) | RU2011124527A (es) |
| TW (1) | TW201021831A (es) |
| WO (1) | WO2010057109A1 (es) |
| ZA (1) | ZA201102998B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004026470D1 (de) | 2003-11-05 | 2010-05-20 | Roche Glycart Ag | Fc-rezeptor und effektorfunktion |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| SI2946765T1 (sl) | 2014-05-23 | 2016-11-30 | Ares Trading S.A. | Tekoči farmacevtski sestavek |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| KR20170005142A (ko) * | 2014-05-27 | 2017-01-11 | 아카데미아 시니카 | 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법 |
| EP3053572A1 (en) * | 2015-02-06 | 2016-08-10 | Ares Trading S.A. | Liquid pharmaceutical composition |
| HK1252158A1 (zh) * | 2015-05-01 | 2019-05-17 | Genentech, Inc. | 掩蔽抗cd3抗體和使用方法 |
| TWI791471B (zh) | 2016-11-15 | 2023-02-11 | 美商建南德克公司 | 用於用抗ｃｄ２０/抗ｃｄ３雙特異性抗體進行治療之給藥 |
| AU2017364077A1 (en) | 2016-11-22 | 2019-06-20 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| BR112019022873A8 (pt) | 2017-05-02 | 2023-04-11 | Merck Sharp & Dohme | Formulação, e, vaso ou dispositivo de injeção. |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| US11077059B2 (en) | 2017-07-25 | 2021-08-03 | Elektrofi, Inc. | Electrospraying formation of particles including agents |
| US12115262B2 (en) | 2018-05-24 | 2024-10-15 | Elektrofi, Inc. | Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| WO2020160323A2 (en) | 2019-01-31 | 2020-08-06 | Elektrofi, Inc. | Particle formation and morphology |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| WO2020264313A1 (en) * | 2019-06-28 | 2020-12-30 | Zymo Research Corporation | Compositions for the stabilization of cell-free nucleic acids and methods thereof |
| EP4027978A1 (en) | 2019-09-13 | 2022-07-20 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
| JP2023522627A (ja) | 2020-04-17 | 2023-05-31 | エレクトロフィ，インコーポレイテッド | 連続的な液滴形成及び脱水によって粒子を形成する方法 |
| CN113797162B (zh) * | 2020-06-17 | 2023-05-05 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂 |
| US12351643B2 (en) | 2020-11-04 | 2025-07-08 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| WO2022241235A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| TW202519266A (zh) | 2022-04-13 | 2025-05-16 | 美商建南德克公司 | 莫蘇妥珠單抗之醫藥組成物及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1234383A (en) * | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| EP2301966A1 (en) * | 2002-12-16 | 2011-03-30 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| UA91961C2 (ru) * | 2003-04-09 | 2010-09-27 | Дженентек, Инк. | Лечение аутоимунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
| ZA200701715B (en) * | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
| WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| JP2010531137A (ja) * | 2007-06-12 | 2010-09-24 | ワイス・エルエルシー | 抗ｃｄ２０治療用組成物および方法 |
-
2009
- 2009-11-16 PE PE2011001039A patent/PE20120204A1/es not_active Application Discontinuation
- 2009-11-16 TW TW098138928A patent/TW201021831A/zh unknown
- 2009-11-16 KR KR1020117011109A patent/KR20110097772A/ko not_active Ceased
- 2009-11-16 RU RU2011124527/10A patent/RU2011124527A/ru not_active Application Discontinuation
- 2009-11-16 WO PCT/US2009/064613 patent/WO2010057109A1/en active Application Filing
- 2009-11-16 EP EP09826921A patent/EP2358394A4/en not_active Withdrawn
- 2009-11-16 BR BRPI0916042A patent/BRPI0916042A2/pt not_active IP Right Cessation
- 2009-11-16 PE PE2014001174A patent/PE20142332A1/es not_active Application Discontinuation
- 2009-11-16 JP JP2011536561A patent/JP2012509270A/ja not_active Ceased
- 2009-11-16 CN CN201310481798.1A patent/CN103705930A/zh active Pending
- 2009-11-16 AR ARP090104435A patent/AR074196A1/es unknown
- 2009-11-16 MX MX2011005056A patent/MX2011005056A/es active IP Right Grant
- 2009-11-16 AU AU2009313756A patent/AU2009313756B2/en not_active Expired - Fee Related
- 2009-11-16 CA CA2742990A patent/CA2742990A1/en not_active Abandoned
- 2009-11-16 CN CN2009801546655A patent/CN102281902B/zh not_active Expired - Fee Related
- 2009-11-16 KR KR1020147027470A patent/KR20140133588A/ko not_active Ceased
-
2011
- 2011-04-20 ZA ZA2011/02998A patent/ZA201102998B/en unknown
- 2011-04-28 IL IL212532A patent/IL212532A0/en unknown
- 2011-05-13 US US13/107,082 patent/US20110300135A1/en not_active Abandoned
- 2011-05-16 CL CL2011001131A patent/CL2011001131A1/es unknown
-
2013
- 2013-11-26 US US14/090,259 patent/US20140308270A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015061508A patent/JP2015157820A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012509270A (ja) | 2012-04-19 |
| CL2011001131A1 (es) | 2012-02-03 |
| CN102281902A (zh) | 2011-12-14 |
| EP2358394A1 (en) | 2011-08-24 |
| IL212532A0 (en) | 2011-06-30 |
| PE20142332A1 (es) | 2015-01-29 |
| CA2742990A1 (en) | 2010-05-20 |
| CN103705930A (zh) | 2014-04-09 |
| KR20140133588A (ko) | 2014-11-19 |
| EP2358394A4 (en) | 2013-03-06 |
| KR20110097772A (ko) | 2011-08-31 |
| AU2009313756A1 (en) | 2010-05-20 |
| AR074196A1 (es) | 2010-12-29 |
| WO2010057109A1 (en) | 2010-05-20 |
| CN102281902B (zh) | 2013-11-13 |
| HK1164750A1 (en) | 2012-09-28 |
| US20110300135A1 (en) | 2011-12-08 |
| MX2011005056A (es) | 2011-05-31 |
| TW201021831A (en) | 2010-06-16 |
| BRPI0916042A2 (pt) | 2015-11-10 |
| JP2015157820A (ja) | 2015-09-03 |
| US20140308270A1 (en) | 2014-10-16 |
| ZA201102998B (en) | 2013-06-26 |
| AU2009313756B2 (en) | 2015-02-26 |
| RU2011124527A (ru) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120204A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| FI3506886T3 (fi) | Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä | |
| CY1122516T1 (el) | Ετοιμες προς χρηση διατυπωσεις κετορολακης | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| AR081200A1 (es) | Formulaciones de insulina de accion prolongada | |
| PE20150615A1 (es) | Inmunoconjugados que comprenden un anticuerpo anti-cd22 ligado a una pirrolobenzodiazepina | |
| IL294463A (en) | Methods for treating or preventing ophthalmological conditions | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| PE20140974A1 (es) | Compuestos de insulina lispro pegilada | |
| JP2016539921A5 (es) | ||
| JP2013517277A5 (es) | ||
| SI2331090T1 (en) | Stable liquid antibody formulation | |
| MX384378B (es) | Dosificación terapéutica de una neurorregulina o una subsecuencia de la misma para el tratamiento o profilaxis de la falla cardiaca. | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| ECSP066477A (es) | Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo | |
| AR074357A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro | |
| RU2019102943A (ru) | Составы на основе антитела | |
| HRP20181021T1 (hr) | Formulacija za bispecifične aktivatore limfocita t (bites) | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| JP2020531523A5 (es) | ||
| UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
| PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
| AR079657A1 (es) | Formulacion de liberacion sostenida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |